Immunosupressive sgent for prostate cancer
Project/Area Number |
16K20152
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Urology
|
Research Institution | Yokohama City University |
Principal Investigator |
Kawahara Takashi 横浜市立大学, 附属市民総合医療センター, 診療講師 (40555570)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
Keywords | 前立腺癌 / 膀胱癌 / 免疫抑制座 / NFATc1 / CRPC / 腫瘍学 |
Outline of Final Research Achievements |
Our study revealed that higher NFATc1 played an iportant role in prostate cancer progression. Immunosupressive agents supressed NFATc1 activity and reulted in supression of prostate cancer progression.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究では現在では治療困難なホルモン抵抗性前立腺癌に対するまったく新し機序の抗腫瘍効果を認める薬剤を確認した。現在、すでに移植領域で使用されている薬剤なので、今後臨床応用がすぐに可能である。
|
Report
(4 results)
Research Products
(9 results)
-
-
-
-
-
-
-
[Journal Article] RANK/RANKL expression in prostate cancer.2017
Author(s)
Ohtaka M, Kawahara T, Mochizuki T, Takamoto D, Hattori Y, Teranishi JI, Miyoshi Y, Yumura Y, Hasumi H, Yokomizo Y, Hayashi N, Kondo K, Yao M, Miyamoto H, Uemura H.
-
Journal Title
Int J Surg Case Rep.
Volume: 30
Pages: 106-106
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-